Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kleb4V vaccine in healthy adults
NCT04959344Phase 2Completed
- Sponsor
- LimmaTech Biologics
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK4429016A in Klebsiella pneumoniae infection (5 arms), sponsored by LimmaTech Biologics. Primary endpoints: Occurrence, severity and relationship of solicited local and general Adverse Events at 7 days, Occurrence, severity and relationship of unsolicited Adverse Events at 28 days and 2 more. Started Jul 2021; status: completed.
02
Drugs
GSK4429016A
03
Conditions
Klebsiella pneumoniae infection
Beyond the preview
Go deeper on NCT04959344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959344.